<DOC>
	<DOCNO>NCT01439204</DOCNO>
	<brief_summary>The purpose study determine whether blood level Abatacept ( BMS-188667 ) drug product manufacture Lonza Biologics Devens , MA facility Bristol-Myers Squibb comparable healthy subject</brief_summary>
	<brief_title>Pharmacokinetic Study Compare Blood Levels Abatacept Manufactured Lonza Biologics Blood Levels Abatacept Manufactured Devens , Massachusetts ( MA ) Facility Bristol-Myers Squibb</brief_title>
	<detailed_description>Primary Purpose study compare pharmacokinetic ( PK ) Abatacept ( BMS-188667 ) manufacture Lonza relative Abatacept ( BMS-188667 ) manufacture Devens , MA facility follow single intravenous infusion 750 mg healthy subject</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Healthy subject determine clinically significant deviation normal medical history , physical examination , electrocardiogram ( ECGs ) , clinical laboratory determination Body weight 60 100 kg , inclusive Any significant acute chronic medical illness Any major surgery within 4 week study drug administration Smoking 10 cigarette per day Recent ( within 6 month study drug administration ) drug alcohol abuse . Positive blood screen hepatitis C antibody , hepatitis B surface antigen , Human Immunodeficiency Virus1 , Human Immunodeficiency Virus2 antibody History significant drug allergy asthma Women pregnant breastfeeding and/or unwilling unable use acceptable method avoid pregnancy entire study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>